---
title: "Basilea Pharmaceutica (OTCMKTS:BPMUF) Sets New 52-Week High  - Should You Buy?"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273756916.md"
description: "Basilea Pharmaceutica (OTCMKTS:BPMUF) reached a new 52-week high of $72.66 during trading, with a volume of 11 shares. The stock's previous close was $72.14, and it has a 50-day moving average of $63.99. The company specializes in biopharmaceuticals, focusing on anti-infectives and oncology. Despite the stock's performance, analysts currently rate it as a Hold, suggesting that there may be better investment opportunities available."
datetime: "2026-01-26T23:02:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273756916.md)
  - [en](https://longbridge.com/en/news/273756916.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273756916.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273756916.md) | [English](https://longbridge.com/en/news/273756916.md)


# Basilea Pharmaceutica (OTCMKTS:BPMUF) Sets New 52-Week High  - Should You Buy?

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $72.66 and last traded at $72.66, with a volume of 11 shares traded. The stock had previously closed at $72.14.

Get **Basilea Pharmaceutica** alerts:

## Basilea Pharmaceutica Price Performance

The stock has a 50-day moving average of $63.99 and a two-hundred day moving average of $64.79. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.32 and a quick ratio of 5.67.

## About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company's research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.

## Featured Articles

-   Five stocks we like better than Basilea Pharmaceutica
-   Your Signature Is Missing – Act Before It’s Too Late
-   What Expenses Can Be Deducted From Capital Gains Tax?
-   “Fed Proof” Your Bank Account with THESE 4 Simple Steps
-   Is Elon Preparing for a Silver Shock?
-   Buy This Stock at 9:30 AM on MONDAY!

_This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._

## Should You Invest $1,000 in Basilea Pharmaceutica Right Now?

Before you consider Basilea Pharmaceutica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basilea Pharmaceutica wasn't on the list.

While Basilea Pharmaceutica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

## 相關資訊與研究

- [BullFrog AI Signs Major AI Drug Discovery Partnership](https://longbridge.com/zh-HK/news/281092205.md)
- [14:37 ETLevrx and Waltz Health Partner to Expand Access to Transparent Pharmacy Pricing](https://longbridge.com/zh-HK/news/281411704.md)
- [TippingPoint Biosciences Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancer](https://longbridge.com/zh-HK/news/281175947.md)
- [08:27 ETinThought Announces the Promotion of Dr. Amanda Weyerbacher to Executive VP](https://longbridge.com/zh-HK/news/281186594.md)
- [Boeing Stock Looks Ugly Now, But It’s an Awakening Giant. How BA Could Be Worth $300 Billion by 2030.](https://longbridge.com/zh-HK/news/281567280.md)